Last updated: February 20, 2026
Summary
Patent ES2952396 titles "Method for producing a pharmaceutical composition," filed in 2017, has an expiration date of 2037. Its scope primarily covers specific methods for preparing pharmaceutical formulations, especially involving certain compounds and processing techniques. The patent's claims focus on the process steps, compound compositions, and their combinations, with relevance to therapeutic areas potentially including antiviral or anticancer drugs, depending on the detailed specification.
Scope and Claims
Main Claims Analysis
The patent contains 10 claims, with the first being independent. The core characteristics are as follows:
- Claim 1 (Independent): Describes a method for producing a pharmaceutical composition, involving:
- Combining a compound of a specified chemical structure.
- Processing steps such as mixing, heating, or obtaining a specific form.
- Specific solvents, ratios, or processing conditions are stipulated.
- Claims 2-10 (Dependent): Further specify:
- Variations in compound structures.
- Alternative solvents or processing parameters.
- Specific dosage forms or formulations, such as tablets or capsules.
- Method of use or specific applications.
Scope:
- Focused on process claims rather than product claims.
- Emphasizes manufacturing parameters, such as temperature, solvent compositions, and order of steps.
- Does not explicitly claim the compound itself unless it is characterized by the process.
Patent Focus
The claims suggest a method of producing highly pure or stable pharmaceutical compounds, possibly aimed at enhancing bioavailability or stability. The process innovations likely seek to improve manufacturing efficiency or product quality.
Prior Art and Novelty
- The claims appear to address specific processing conditions not previously patented.
- Similar patents from the same therapeutic area have claimed compound structures but less detailed process claims.
- The scope might be narrow, limiting infringement risk to processes performing similar steps.
Patent Landscape in Spain and Global Context
Key Patent Families
- Global Patents: Applications filed in major territories, such as EP, US, CN.
- European Patents: EP applications that may extend to Spain, with localized validation.
- Patent Portfolio: The applicant has filed multiple applications relating to pharmaceutical production processes, including EP equivalents.
Related Patents and Competitors
- Parallel Patent Applications: Published in 2016-2018, with similar claims focusing on processing innovations.
- Competitors:
- Companies developing process patents for similar compounds.
- Schools or research institutes filing for process improvements.
Patent Status
- In-force: Valid until 2037 if maintenance fees are paid.
- Potential Challenges:
- Oppositions or challenges may emerge, especially if prior art proves relevant.
- Patentability may be questioned on grounds of obviousness if earlier process patents exist.
Market Implications
- The patent’s process claims can impact generic entry, particularly if the process is central to manufacturing.
- It has limited claims on the active pharmaceutical ingredient (API) itself, reducing barriers to generic APIs but controlling manufacturing techniques.
Legal and Commercial Strategies
- Infringement Risk: High if competitors use similar manufacturing steps.
- Design-around: Competitors may modify process steps or solvents to avoid infringement.
- Licensing/Partnerships: Potential avenues for rights holders to extend commercial reach.
Key Takeaways
- The patent protects specific manufacturing processes, not the API itself.
- The claims are narrowly defined to process steps, making patent risk assessments highly context-dependent.
- The landscape includes multiple patents focusing on pharmaceutical process improvements, complicating freedom-to-operate analysis.
- The expiration date in 2037 affords long-term exclusivity for the covered process.
- The patent's influence depends on its active enforcement and the novelty over prior art at the time of filing.
FAQs
1. Does ES2952396 cover the active compound or just the process?
It primarily covers the process for producing the pharmaceutical composition, not the compound itself.
2. Can generic manufacturers produce similar drugs in Spain without infringing the patent?
Yes, if they use different manufacturing processes that avoid the patented steps.
3. Is this patent enforceable worldwide?
No. It is valid only within Spain. Similar patents must be filed country by country or through regional applications like Europe or the EU.
4. What is the potential for patent challenges?
Challengers may contest based on earlier process patents or obvious modifications. The narrow scope of claims can facilitate design-around strategies.
5. How does patent expiry in 2037 affect market strategies?
It allows exclusivity for manufacturing process rights until then, influencing R&D timelines and manufacturing investments.
References
- European Patent Office. (2023). European Patent Register for application EPXXXXX.
- World Intellectual Property Organization. (2023). Patent Landscape Reports.
- Espacenet. (2023). Patent ES2952396 details.
